14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
UL vs CLX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CLX Overall Winner
6-Pillar Tally: UL 2 – 4 CLX
Matrix Metrics: UL 6 – 4 CLX
As of Nov 20, 2026, Clorox Company (CLX) is the stronger overall head-to-head candidate over Unilever plc (UL) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). UL carries a Unified Composite Score of 46.7/100 (HOLD) at $63.82 (18.5x Forward P/E, 20.0% operating margin), whereas CLX carries 29.7/100 (SELL) at $104.73 (17.6x Forward P/E, 14.3% operating margin).
Composite vs. Pillar Nuance: While UL currently prints a higher short-term Unified Composite Score (46.7/100 HOLD vs. CLX 29.7/100 SELL), CLX captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 20.0% operating margin) and revenue trajectory (+33.3% vs. +0.5% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UL vs CLX. Trailing 12-month operating profitability (UL 20.0% vs CLX 14.3%) and valuation multiples (UL 18.5x vs CLX 17.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Household & Personal Products value chain with $136.4B market capitalization and 20.0% operating margin.
OpEx & R&D Reinvestment27.1% of Rev ($13.7B)
90D Engineering Disclosures0 Published
CLX Moat ProfileHigh-Margin Pricing Power Moat
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $12.7B market capitalization and 14.3% operating margin.
OpEx & R&D Reinvestment27.6% of Rev ($1.99B)
90D Engineering Disclosures0 Published
Investor FAQ UL vs CLX Key Questions & Quantitative Answers
As of Nov 20, 2026, Clorox Company (CLX) is the stronger overall head-to-head candidate over Unilever plc (UL) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). UL carries a Unified Composite Score of 46.7/100 (HOLD) at $63.82 (18.5x Forward P/E, 20.0% operating margin), whereas CLX carries 29.7/100 (SELL) at $104.73 (17.6x Forward P/E, 14.3% operating margin). Composite vs. Pillar Nuance: While UL currently prints a higher short-term Unified Composite Score (46.7/100 HOLD vs. CLX 29.7/100 SELL), CLX captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 20.0% operating margin) and revenue trajectory (+33.3% vs. +0.5% YoY).
CLX leads the Growth & Scale pillar: UL posts +0.5% YoY revenue growth and -5.6% YoY earnings growth on $50.6B TTM revenue (47.1% gross margin, 20.0% operating margin), compared with CLX at +33.3% YoY revenue growth and +113.8% YoY earnings growth on $7.20B TTM revenue (41.9% gross margin, 14.3% operating margin). On trailing 12-month operating scale, UL generates $50.6B in USD-normalized revenue versus $7.20B for CLX. In operating R&D and SG&A reinvestment, UL deploys 27.1% of Rev ($13.7B) (0 90-day corporate R&D disclosures) versus 27.6% of Rev ($1.99B) (0 disclosures) for CLX.
CLX screens cheaper on headline valuation multiples. UL trades at 18.5x Forward P/E, 13.0x Trailing P/E, 6.93x PEG, and 2.7x EV/Revenue (21.5% EBITDA margin), whereas CLX trades at 17.6x Forward P/E, 18.9x Trailing P/E, 1.62x PEG, and 2.5x EV/Revenue (6.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UL (31.9% ROE) versus CLX (53.4% ROE) capital efficiency.
In options market volatility and institutional positioning, UL carries 13.8% implied volatility (13th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.03β · 24% Vol realized risk). By comparison, CLX carries 44.8% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.53x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.43β · 37% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.